Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway

Cancer Research

Volumn 66, Issue 20, 2006, Pages 10083-10091

  Cozzi, Sarah Jane ^a   Parsons, Peter G ^a   Ogbourne, Steven M ^a   Pedley, Julie ^a   Boyle, Glen M ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1; DITERPENE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PEP 005; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL GROWTH; DEPHOSPHORYLATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; SILENCER ELEMENT;

CELL AGING; CELL CYCLE; CELL LINE, TUMOR; DITERPENES; E2F1 TRANSCRIPTION FACTOR; ENZYME ACTIVATION; ESTERS; GENE SILENCING; HUMANS; ISOENZYMES; MAP KINASE SIGNALING SYSTEM; MELANOMA; PHOSPHORYLATION; PROTEIN KINASE C; RETINOBLASTOMA PROTEIN; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION, GENETIC;

EID: 33750536856     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0348     Document Type: Article

References (52)

1. Kedei N, Lundberg DJ, Toth A, Welburn P, Garfield SH, Blumberg PM. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res 2004;64:3243-55.
2. Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res 2004;64:2833-9.
3. Hampson P, Chahal H, Khanim F, et al. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the δ isoform of PKC. Blood 2005;106:1362-8.
4. Han ZT, Tong YK, He LM, et al. 12-O-Tetradecanoyl-phorbol-13-acetate (TPA)-induced increase in depressed white blood cell counts in patients treated with cytotoxic cancer chemotherapeutic drugs. Proc Natl Acad Sci U S A 1998;95:5362-5.
5. Han ZT, Zhu XX Yang RY, et al. Effect of intravenous infusions of 12-0-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity. Proc Natl Acad Sci U S A 1998;95:5357-61.
6. Hofmann J. Modulation of protein kinase C in antitumor treatment. Rev Physiol Biochem Pharmacol 2001;142:1-96.
7. Lang W, Wang H, Ding L, Xiao L. Cooperation between PKC-α and PKC-epsilon in the regulation of JNK activation in human lung cancer cells. Cell Signal 2004;16:457-67.
8. Ueda Y, Hirai S, Osada S, Suzuki A, Mizuno K, Ohno S. Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem 1996;271:23512-9.
9. Pan J, Singh US, Takahashi T, et al. PKC mediates cyclic stretch-induced cardiac hypertrophy through Rho family GTPases and mitogen-activated protein kinases in cardiomyocytes. J Cell Physiol 2005;202:536-53.
10. Lu Z, Liu D, Hornia A, Devonish W, Pagano M, Foster DA. Activation of protein kinase C triggers its ubiquitination and degradation. Mol Cell Biol 1998;18:839-45.
11. Fox E, Curt GA, Balls FM. Clinical trial design for target-based therapy. Oncologist 2002;7:401-9.
12. Hoekstra R, Verweij J, Eskens FA. Clinical trial design for target specific anticancer agents. Invest New Drugs 2003;21:243-50.
13. Kahlem P, Dorken B, Schmitt CA. Cellular senescence in cancer treatment: friend or foe? J Clin Invest 2004;113:169-74.
14. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002;62:1876-83.
15. Chang BD, Broude EV, Dokmanovic M, et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999;59:3761-7.
16. Jaiswal AS, Multani AS, Pathak S, Narayan S. N-methyl-N′-nitro-N- nitrosoguanidine-induced senescence-like growth arrest in colon cancer cells is associated with loss of adenomatous polyposis coli protein, microtubule organization, and telomeric DNA. Mol Cancer 2004;3:3.
17. Chang BD, Swift ME, Shen M, Fang J, Broude EV, Roninson IB. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci U S A 2002;99:389-94.
18. Pavey S, Johansson P, Packer L, et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 2004;23:4060-7.
19. Xu C, Parsons PG. Cell cycle delay, mitochondrial stress and uptake of Hydrophobic cations induced by sunscreens in cultured human cells. Photochem Photobiol 1999;69:611-6.
20. Chen TR. In situ detection of Mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 1977;104:255-62.
21. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
22. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
23. Visala Rao D, Boyle GM, Parsons PG, Watson K, Jones GL. Influence of ageing, heat shock treatment and in vivo total antioxidant status on gene-expression profile and protein synthesis in human peripheral lymphocytes. Mech Ageing Dev 2003;124:55-69.
24. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR Nucleic Acids Res 2001;29:e45.
25. Leonard JH, Cook AL, Van Gele M, et al. Proneural and proneuroendocrine transcription factor expression in cutaneous mechanoreceptor (Merkel) cells and Merkel cell carcinoma. Int J Cancer 2002;101:103-10.
26. Arita Y, O'Driscoll KR, Weinstein IB. Growth inhibition of human melanoma-derived cells by 12-O-tetradecanoyl phorbol 13-acetate. Int J Cancer 1994;56:229-35.
27. 1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity. Exp Cell Res 1995;221:92-102.
28. 2 in metastatic melanoma cells: inhibition of phosphorylation of p34cdc2. Cell Growth Differ 1992;3:485-94.
29. Arita Y, O'Driscoll KR, Weinstein IB. Growth of human meianocyte cultures supported by 12-O-tetradecanoylphorbol-13-acetate is mediated through protein kinase C activation. Cancer Res 1992;52:4514-21.
30. Harrington L. Biochemical aspects of telomerase function. Cancer Lett 2003;194:139-54.
31. Castellano M, Pollock PM, Walters MK, et al. CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res 1997;57:4868-75.
32. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
33. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994;102:285-90.
34. Sers C, Emmenegger U, Husmann K, Bucher K, Andres AC, Schafer R. Growth-inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev107 in tumor cell lines and experimental tumors. J Cell Biol 1997;136:935-44.
35. Hajnal A, Klemenz R, Schafer R. Subtraction cloning of H-rev107, a gene specifically expressed in H-ras resistant fibroblasts. Oncogene 1994;9:479-90.
36. Ishida S, Huang E, Zuzan H, et al. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 2001;21:4684-99.
37. Kanazawa S, Fujiwara Y, Mizuno K. Selective repression of growth-regulating cdk2, cyclin E and E2F1 genes in human cell senescence. Kobe J Med Sci 1994;40:165-74.
38. Saunders NA, Smith RJ, Jetten AM. Regulation of proliferation-specific and differentiation-specific genes during senescence of human epidermal keratinocyte and mammary epithelial cells. Biochem Biophys Res Commun 1993;197:46-54.
39. Ren B, Cam H, Takahashi Y, et al. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev 2002;16:245-56.
40. Cacace AM, Ueffing M, Philipp A, Han EK, Kolch W, Weinstein IB. PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase. Oncogene 1996;13:2517-26.
41. Kolch W, Heidecker G, Kochs G, et al. Protein kinase Cα activates RAF-1 by direct phosphorylation. Nature 1993;364:249-52.
42. Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychene A, Mascarelli F. Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J Biol Chem 2003;278:42409-18.
43. Hamilton M, Liao J, Cathcart MK, Wolfman A. Constitutive association of c-N-Ras with c-Raf-1 and protein kinase C epsilon in latent signaling modules. J Biol Chem 2001;276:29079-90.
44. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
45. Park WY, Park JS, Cho KA, et al. Up-regulation of caveolin attenuates epidermal growth factor signaling in senescent cells. J Biol Chem 2000;275:20847-52.
46. Tresini M, Lorenzini A, Frisoni L, Allen RG, Cristofalo VJ. Lack of Elk-1 phosphorylation and dysregulation of the extracellular regulated kinase signaling pathway in senescent human fibroblast. Exp Cell Res 2001;269:287-300.
47. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
48. Zhu J, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998;12:2997-3007.
49. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-4.
50. Deng Q, Liao R, Wu BL, Sun P. High intensity ras signaling induces premature senescence by activating p38 pathway in primary human fibroblasts. J Biol Chem 2004;279:1050-9.
51. Sebastian T, Malik R, Thomas S, Sage J, Johnson PF. C/EBPβ cooperates with RB:E2F to implement Ras(V12)-induced cellular senescence. EMBO J 2005;24:3301-12.
52. Roder K, Latasa MJ, Sul HS. Silencing of the mouse H-rev107 gene encoding a class II tumor suppressor by CpG methylation. J Biol Chem 2002;277:30543-50.